What Can You Tell Me About Potential COVID-19 Vaccines in Children? Hear About Some of Pfizer’s Research

Since early summer 2021, cases of COVID-19 in children have been rising in the U.S., and as the Delta variant has become the dominant strain, cases continue to grow each day. Pfizer has been working to determine and evaluate the preferred vaccine dose to provide protection against COVID-19 in children.

Bill Gruber, MD, Senior Vice President of Clinical Research and Development at Pfizer, is Board Certified in Pediatrics and Pediatric Infectious Diseases and has more than 35 years of experience in vaccine development. He has a passion for the welfare of children and prevention of infectious diseases, and here he shares an inside look at the recent late-stage pediatric study.

Q: Bill, the company provided a first look at the study’s results. What were those results and what does that mean for kids?

A: Our late-stage Phase 2/3 study for kids 5-11 years old showed the Pfizer-BioNTech COVID-19 vaccine generated a strong immune response that compares well to what we saw in people between the ages of 16 to 25 years old in our Phase 3 landmark study. The data from the Phase 2/3 study also showed that our vaccine was well tolerated in kids 5-11 years old, with side effects generally similar to or lower than what we saw in the 16 to 25 year old group.

Q: Do you know how effective the vaccine is in protecting kids 5-11 years old?

While the immune responses we saw in the study in the 5-11 year old group predicts that the vaccine is likely to provide protection, we have not had enough cases to determine efficacy.  We are continuing to evaluate efficacy in this study.

Q: Why is the dose smaller?

A: From the beginning of the pandemic we have strived to determine a vaccine dose that provides protection against COVID-19 in adults and children. In this study we intended to find a dose level that was well tolerated and still produced a high immune response in kids 5-11 years old. We believe that a dose level of 10 ug, one third of the dose used in people 12 and older, did just that.

Q: Were there any cases of myocarditis or pericarditis seen?

A: We have not seen any cases of myocarditis or pericarditis in our clinical trials. However, we are aware of the rare reports of myocarditis, especially in young males, following vaccination. According to health authorities this is an extremely rare side effect, and it is important to note that health authorities continues to strongly encourage COVID-19 vaccinations for those eligible. We’ll also continue to monitor this through pharmacovigilance.

Q: What is the expected timing for potential emergency use authorization (EUA)?

A: We have already begun sharing data with the U.S. Food and Drug Administration (FDA) and we plan to submit to request Emergency Use Authorization in kids 5-11 years old as soon as possible.

Q: What is the expected timing for kids younger than 5 years old?

A: We expect to potentially have some data for kids 2-4 years old in the fourth quarter of this year and kids between 6 months and 2 years old sometime after that. Provided that the data demonstrate safety and immunogenicity, and in agreement with regulators, we could potentially submit the data to request EUA shortly after the data readouts.

Q: Will vaccinating this new population affect supply?

A: Rolling out vaccine doses to this age group is not expected to impact the supply agreements that Pfizer and BioNTech have in place with governments and non-government organizations (NGOs) around the world. From day one, our goal has been to provide fair and equitable access to the vaccine to everyone, everywhere.

In addition, the information contained on this site, including scientific approaches, assumptions regarding potential safety and efficacy, clinical trial and manufacturing plans and timing estimates, are subject to change based on emerging data, regulatory guidance, and manufacturing and technical developments, among other risks.

Join Pfizer Investor Insights

Sign up to receive important updates about Pfizer, how we’re innovating for patients and delivering value for shareholders. Email updates will also provide exciting opportunities for individual shareholders to hear from our leadership and experts.

I would like to receive information, updates, and hear from leadership regarding Pfizer Investor Insights and other investor relations initiatives in accordance with Pfizer’s Privacy Policy.